Allogene Therapeutics CFO Geoffrey Parker to retire in November 2026
The company disclosed in an SEC filing that its finance chief will step down effective November 6, 2026.
Allogene Therapeutics, Inc. reported in an 8-K filing dated September 2, 2026 that Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of the company, notified Allogene of his retirement from all positions, with the departure taking effect on November 6, 2026.1
The notice was given on August 31, 2026, according to the filing, which lists that date as the reported event.
The 8-K was filed under Item 5.02, which covers departures and appointments of officers and directors. It does not name a successor CFO or provide additional detail on transition plans.
The filing was signed by Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics, Inc., and dated September 2, 2026.1 Allogene Therapeutics is a Delaware-incorporated company headquartered in South San Francisco, California, and its common stock trades on the Nasdaq Stock Market under the ticker symbol ALLO, per the filing's cover page.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.